← Russell 3000 cross-section

PAHC PHIBRO ANIMAL HEALTH CORP

Trailing twelve months to 2026-06-30 · as filed 2026-08-26, not restated
Healthcare

Scale

Market cap
$1.5bn
Revenue TTM
$1.5bn
Net income TTM
$100m
Free cash flow
$10m
Composite score
71.2
Sector rank
#1813

Valuation

P / E
14.6
EV / EBITDA
5.6
EV / sales
0.9
FCF yield
0.68%
Earnings yield vs 10-yr
2.11pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
6.6%
EBITDA margin
16.2%
ROE
25.9%
ROIC
64.0%
Revenue growth
17.1%

Insider activity, last 90 days

Net open-market
$0.32m
Buyers
1
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Since the Acquisition, the product portfolio acquired has contributed $478.7 million to our overall net sales, of which $95.9 million and $77.0 million were recorded in the three months ended March 31, 2026 and 2025, and $270.5 million and $113.7 million were recorded in the nine months ended March 31, 2026 and 2025, respectively. Our Israeli manufacturing facilities and local operations account for 17% of our consolidated assets as of March 31, 2026, and 16% of our consolidated net sales for the nine months ended March 31, 2026. Our sales to Russia and Ukraine for the twelve months ended March 31, 2026 represented approximately 1% of consolidated net sales. …PHIBRO ANIMAL HEALTH CORP, 10-Q, period ended 2026-03-31, filed 2026-05-06

Read the full passage →